Key result
Early therapy with glycoprotein IIb/IIIa inhibition, aspirin, and clopidogrel is supported by guidelines for high-risk patients with acute coronary syndrome and elevated cardiac biomarkers.
Population
Patients with acute coronary syndrome, particularly high-risk patients with elevated cardiac biomarkers…
Design
Review
Authors
Loading...
Affirms guideline-directed early antiplatelet therapy in high-risk ACS; leaves open optimization with contemporary P2Y12 agents.
High platelet reactivity is a potent cardiovascular risk factor in acute coronary syndrome, necessitating early and intensive antiplatelet therapy in high-risk patients.
Gurbel et al. (2008) conducted a review in Acute Coronary Syndrome. Antiplatelet Treatments was evaluated. Early therapy with glycoprotein IIb/IIIa inhibition, aspirin, and clopidogrel is supported by guidelines for high-risk patients with acute coronary syndrome and elevated cardiac biomarkers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: